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Background
Lynch syndrome is an autosomal dominant cancer sus-
ceptibility syndrome that accounts for approximately 2–
4% of all colorectal cancers (CRCs) and is caused by
germline mutations of mismatch repair (MMR) genes
[1-4]. It is characterized by an early onset of predomi-
nantly CRC and endometrial cancer (EC) as well as can-
cers of the stomach, small bowel, ureter and renal pelvis.
Materials and methods
We report a case of a patient 60 years old affected by
synchronous primary cancers of the sigma and stomach
diagnosed by TC. The patient had previously been oper-
ated on for the right hemicolectomy for adenocarci-
noma, and hysterectomy for cancer. During
hospitalization the patient has undergone surgery on the
left hemicolectomy and a total gastrectomy. The patient
underwent chemotherapy. Currently the patient is
receiving chemotherapy for local recurrence.
Results
As a result of genetic study, the patient was found to be
the first to have this mutation.
Conclusions
S u r g e r yr e m a i n st h ef r o n t - l i n et h e r a p yf o rH N P C C .
There is an ongoing controversy over the benefit of 5-
fluorouracil-based adjuvant therapies for HNPCC-
related colorectal tumors, particularly those in stages I
and II. After reporting a null finding from their rando-
mized controlled trial of aspirin (ASA) to prevent
against the colorectal neoplasia of Lynch Syndrome,
Burn and colleagues have recently reported new data,
representing a longer follow-up period than reported in
the initial NEJM paper. These new data demonstrate a
reduced incidence in Lynch Syndrome patients who
were exposed to at least four years of high-dose aspirin,
w i t has a t i s f a c t o r yr i s kp r o f i l e .T h e s er e s u l t sh a v eb e e n
widely covered in the media; future studies will look at
modifying (lowering) the dose (to reduce risk associated
with the high dosage of ASA).
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